Mount-Royal, Canada

Robert Déziel

USPTO Granted Patents = 3 

 

Average Co-Inventor Count = 4.3

ph-index = 1

Forward Citations = 52(Granted Patents)


Company Filing History:


Years Active: 2013-2014

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Robert Déziel

Introduction

Robert Déziel is a notable inventor based in Mount-Royal, Canada. He has made significant contributions to the field of biochemistry, particularly in the development of inhibitors for histone deacetylase. With a total of three patents to his name, Déziel's work has implications for treating various cell proliferative diseases.

Latest Patents

One of Déziel's latest patents is titled "Inhibitors of histone deacetylase and prodrugs thereof." This invention focuses on the inhibition of histone deacetylase, providing compounds and prodrugs that can effectively inhibit the enzymatic activity of this target. The invention also outlines compositions and methods for treating cell proliferative diseases and conditions. Another significant patent is simply titled "Inhibitors of histone deacetylase," which similarly addresses the inhibition of histone deacetylase and offers compounds and methods for therapeutic applications.

Career Highlights

Throughout his career, Robert Déziel has worked with prominent companies in the pharmaceutical industry, including Methylgene, Inc. and Envivo Pharmaceuticals, Inc. His experience in these organizations has allowed him to further develop his innovative ideas and contribute to advancements in medical treatments.

Collaborations

Some of Déziel's notable coworkers include Pierre Tessier and David Smil. Their collaborative efforts have likely played a role in the success of his inventions and patents.

Conclusion

Robert Déziel's contributions to the field of biochemistry through his patents on histone deacetylase inhibitors highlight his innovative spirit and dedication to advancing medical science. His work continues to influence the development of treatments for cell proliferative diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…